Literature DB >> 21495177

Observations on intelligence and behavior in 15 patients with Legius syndrome.

Ellen Denayer1, Mie-Jef Descheemaeker, Douglas R Stewart, Kathelijn Keymolen, Ellen Plasschaert, Sarah L Ruppert, Joseph Snow, Audrey E Thurm, Lisa A Joseph, Jean-Pierre Fryns, Eric Legius.   

Abstract

Legius syndrome is a RAS-MAPK syndrome characterized by pigmentary findings similar to neurofibromatosis type 1 (NF1), but without tumor complications. Learning difficulties and behavioral problems have been reported to be associated with Legius syndrome, but have not been studied systematically. We investigated intelligence and behavior in 15 patients with Legius syndrome and 7 unaffected family members. We report a mean full-scale IQ of 101.57 in patients with Legius syndrome, which does not differ from the control group. We find a significantly lower Performance IQ in children with Legius syndrome compared to their unaffected family members. Few behavioral problems are present as assessed by the Child Behavior Checklist (CBCL) questionnaire. Our observations suggest that, akin to the milder somatic phenotype, the cognitive phenotype in Legius syndrome is less severe than that of NF1. 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21495177      PMCID: PMC3081633          DOI: 10.1002/ajmg.c.30297

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  14 in total

1.  Learning deficits, but normal development and tumor predisposition, in mice lacking exon 23a of Nf1.

Authors:  R M Costa; T Yang; D P Huynh; S M Pulst; D H Viskochil; A J Silva; C I Brannan
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

Review 2.  Cognitive profile of neurofibromatosis type 1.

Authors:  Terry M Levine; April Materek; Jessica Abel; Madeline O'Donnell; Laurie E Cutting
Journal:  Semin Pediatr Neurol       Date:  2006-03       Impact factor: 1.636

Review 3.  Cognitive deficits in neurofibromatosis 1.

Authors:  Kathryn North; Shelley Hyman; Belinda Barton
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

4.  The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.

Authors:  Weidong Li; Yijun Cui; Steven A Kushner; Robert A M Brown; J David Jentsch; Paul W Frankland; Tyrone D Cannon; Alcino J Silva
Journal:  Curr Biol       Date:  2005-11-08       Impact factor: 10.834

5.  Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1.

Authors:  Rui M Costa; Nikolai B Federov; Jeff H Kogan; Geoffrey G Murphy; Joel Stern; Masuo Ohno; Raju Kucherlapati; Tyler Jacks; Alcino J Silva
Journal:  Nature       Date:  2002-01-16       Impact factor: 49.962

6.  A mouse model for the learning and memory deficits associated with neurofibromatosis type I.

Authors:  A J Silva; P W Frankland; Z Marowitz; E Friedman; G S Laszlo; D Cioffi; T Jacks; R Bourtchuladze; G Lazlo
Journal:  Nat Genet       Date:  1997-03       Impact factor: 38.330

7.  SPRED 1 mutations in a neurofibromatosis clinic.

Authors:  Talia M Muram-Zborovski; David A Stevenson; David H Viskochil; David C Dries; Andrew R Wilson
Journal:  J Child Neurol       Date:  2010-02-22       Impact factor: 1.987

8.  Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.

Authors:  Lianne C Krab; Arja de Goede-Bolder; Femke K Aarsen; Saskia M F Pluijm; Marlies J Bouman; Jos N van der Geest; Maarten Lequin; Coriene E Catsman; Willem Frans M Arts; Steven A Kushner; Alcino J Silva; Chris I de Zeeuw; Henriëtte A Moll; Ype Elgersma
Journal:  JAMA       Date:  2008-07-16       Impact factor: 56.272

9.  Spred1 is required for synaptic plasticity and hippocampus-dependent learning.

Authors:  Ellen Denayer; Tariq Ahmed; Hilde Brems; Geeske Van Woerden; Nils Zuiderveen Borgesius; Zsuzsanna Callaerts-Vegh; Akihiko Yoshimura; Dieter Hartmann; Ype Elgersma; Rudi D'Hooge; Eric Legius; Detlef Balschun
Journal:  J Neurosci       Date:  2008-12-31       Impact factor: 6.167

Review 10.  Clinical and molecular aspects of RAS related disorders.

Authors:  E Denayer; Th de Ravel; E Legius
Journal:  J Med Genet       Date:  2008-06-11       Impact factor: 6.318

View more
  7 in total

Review 1.  Modeling cognitive dysfunction in neurofibromatosis-1.

Authors:  Kelly A Diggs-Andrews; David H Gutmann
Journal:  Trends Neurosci       Date:  2013-01-08       Impact factor: 13.837

2.  Neurofibromatosis type 1 (NF1) associated with tumor of the corpus callosum.

Authors:  Ignacio Pascual-Castroviejo; Samuel-Ignacio Pascual-Pascual
Journal:  Childs Nerv Syst       Date:  2012-09-22       Impact factor: 1.475

3.  Central precocious puberty in a girl with LEGIUS syndrome: an accidental association?

Authors:  Valentina Orlandi; Paolo Cavarzere; Laura Palma; Rossella Gaudino; Franco Antoniazzi
Journal:  Ital J Pediatr       Date:  2021-03-04       Impact factor: 2.638

Review 4.  Legius syndrome: case report and review of literature.

Authors:  Elisa Benelli; Irene Bruno; Chiara Belcaro; Alessandro Ventura; Irene Berti
Journal:  Ital J Pediatr       Date:  2015-02-08       Impact factor: 2.638

5.  Lymphangiopathy in neurofibromatosis 1 manifesting with chylothorax, pericardial effusion, and leg edema.

Authors:  Josef Finsterer; Claudia Stollberger; Elisabeth Stubenberger; Sasan Tschakoschian
Journal:  Int J Gen Med       Date:  2013-09-09

6.  Legius Syndrome and its Relationship with Neurofibromatosis Type 1.

Authors:  Ellen Denayer; Eric Legius
Journal:  Acta Derm Venereol       Date:  2020-03-25       Impact factor: 3.875

7.  MEK inhibition ameliorates social behavior phenotypes in a Spred1 knockout mouse model for RASopathy disorders.

Authors:  Sarah C Borrie; Ellen Plasschaert; Zsuzsanna Callaerts-Vegh; Akihiko Yoshimura; Rudi D'Hooge; Ype Elgersma; Steven A Kushner; Eric Legius; Hilde Brems
Journal:  Mol Autism       Date:  2021-07-26       Impact factor: 7.509

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.